Literature DB >> 19035151

[Epidemiology of prostate cancer from three centers and analysis of the first-line hormonal therapy for the advanced disease].

Chun-guang Ma1, Ding-wei Ye, Chang-ling Li, Fang-jian Zhou, Xu-dong Yao, Shi-lin Zhang, Bo Dai, Hai-liang Zhang, Yao Zhu, Yi-jun Shen.   

Abstract

OBJECTIVES: To analyze the epidemiology information of prostate cancer from three centers of Beijing, Shanghai, Guangzhou, and to reflect the current situation of prostate cancer in China, and to analyze the information of 272 patients with advanced prostate cancer who received hormonal therapy to find the prognostic factors of hormone therapy.
METHODS: Collect the information of 525 patients with prostate cancer from three centers. Two hundred and seventy-two cases of advanced prostate cancer with full information were selected from the 525 cases to analyze the prognostic factors of hormone therapy.
RESULTS: Three hundred and fifty-seven cases (68.0%) had advanced disease at diagnosis and 80.2% patients received hormone therapy as the main therapy. Prognostic analysis indicated that Gleason score, bone metastasis and prostate specific antigen nadir were independent prognostic factors of progression-free survival time.
CONCLUSIONS: In this report, most patients are advanced prostate cancer at diagnose, and hormonal therapy is the main therapy. Gleason score, bone metastasis, prostate specific antigen nadir are independent prognostic factors of advanced prostate cancer after hormone therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19035151

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  7 in total

1.  Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients.

Authors:  Li-Juan Meng; Jun Wang; Wei-Fei Fan; Xiao-Lin Pu; Fu-Yin Liu; Min Yang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-02       Impact factor: 4.553

2.  MiRNA-671-5p Promotes prostate cancer development and metastasis by targeting NFIA/CRYAB axis.

Authors:  Zhiguo Zhu; Lianmin Luo; Qian Xiang; Jiamin Wang; Yangzhou Liu; Yihan Deng; Zhigang Zhao
Journal:  Cell Death Dis       Date:  2020-11-03       Impact factor: 8.469

3.  A multicenter observational study of the real-world use of docetaxel for metastatic castration-resistant prostate cancer in China.

Authors:  Dalin He; Zhongquan Sun; Jianming Guo; Zhigen Zhang; Yuxi Shan; Lulin Ma; Hanzhong Li; Jie Jin; Yiran Huang; Jiaquan Xiao; Qiang Wei; Dingwei Ye
Journal:  Asia Pac J Clin Oncol       Date:  2019-03-15       Impact factor: 2.601

Review 4.  Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis.

Authors:  Fan Li; Hui Xiang; Zisen Pang; Zejia Chen; Jinlong Dai; Shu Chen; Bin Xu; Tianyu Zhang
Journal:  Cancer Med       Date:  2020-05-26       Impact factor: 4.452

5.  The Effect of an Information Support Program on Self-Efficacy of Prostate Cancer Patients during Hormonal Therapy.

Authors:  Rui Yang; Zhenqi Lu; Xiaofeng Gu; Bo Dai
Journal:  Asia Pac J Oncol Nurs       Date:  2021-10-04

6.  Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial.

Authors:  Xiangwei Yang; Hong Chen; Duanya Xu; Xianju Chen; Yamei Li; Jun Tian; Dongwen Wang; Jun Pang
Journal:  BMC Cancer       Date:  2022-02-16       Impact factor: 4.430

Review 7.  Prostate cancer in East Asia: evolving trend over the last decade.

Authors:  Yao Zhu; Hong-Kai Wang; Yuan-Yuan Qu; Ding-Wei Ye
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.